Sullivan, Bruyette, Speros & Blaney’s GSK GSK Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$121K	Buy	2,716 +2	+0.1%	+$91	0.01%	386
2020 Q4	$125K	Buy	2,714 +3	+0.1%	+$138	0.01%	363
2020 Q3	$128K	Buy	2,711 +2	+0.1%	+$100	0.01%	312
2020 Q2	$138K	Buy	2,709 +3	+0.1%	+$154	0.01%	276
2020 Q1	$128K	Buy	2,706 +882	+48%	+$47K	0.01%	268
2019 Q4	$107K	Buy	+1,824	New	+$101K	0.01%	334

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's GSK Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney increased its GSK (GSK) stake by 0.07% in Q1 2021, buying an estimated $91 and bringing the position to 2,716 shares worth $121K. The position accounts for 0.01% of the portfolio, ranked #386.

Sullivan, Bruyette, Speros & Blaney first reported a position in GSK in Q4 2019 and has held it in 6 quarters since. The position peaked at $138K in Q2 2020. 775 funds tracked by Wall St. Rank hold GSK as of Q1 2021.

Sullivan, Bruyette, Speros & Blaney held 2,716 shares of GSK worth $121K as of Q1 2021.
Sullivan, Bruyette, Speros & Blaney bought 2 GSK shares in Q1 2021, an estimated $91.
GSK made up 0.01% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #386 holding.
Sullivan, Bruyette, Speros & Blaney first reported a position in GSK in Q4 2019 and has held it in 6 quarters since.
Sullivan, Bruyette, Speros & Blaney's GSK position peaked at $138K in Q2 2020.
775 funds tracked by Wall St. Rank held GSK as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.